Research Article| Volume 6, ISSUE 4, P200-212, October 1988

The safety of topical minoxidil solution in the treatment of pattern baldness: The results of a 27-center trial

  • James R. Spinaler
    Address for correspondence: James R. Spindler, MD, The Upjohn Company, 9159-243-104, 7000 Portage Road, Kalamazoo, MI 49001.
    From the Dermatology Clinical Research Unit, The Upjohn Company, Kalamazoo, Michigan USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      Minoxidil (2–4 diamino-6-piperidine-pyrimidine-5-oxide) is a directacting peripheral arteriolar vasodilator that reduces peripheral vascular resistance. It was first marketed by The Upjohn Company in 1979 as Loniten® Tablets for the treatment of severe hypertension. The peripheral vasodilation caused predictable cardiovascular effects, such as lowered blood pressure, reflex tachycardia, and fluid retention.1 Canine cardiac lesions were reported in toxicology studies, but no such findings are evident in humans.2
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinics in Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chidsey CA
        • Gottlieb TB
        The pharmacologie basis of antihypertensive therapy: the role of vasodilator drugs.
        Prog Cardiovasc Dis. 1974; 27: 99-113
        • Sobota JT
        • Martin WB
        • Carlson RG
        • et al.
        Minoxidil: right atrial cardiac pathology in animals and in man.
        Circulation. 1980; 62: 376-387
        • Zappacosta AR
        Reversal of baldness in patients receiving minoxidil for hypertension.
        N Engl J Med. 1981; 18: 1480-1481
        • Seidman M
        • Westfried M
        • Maxey R
        • et al.
        Reversal of male pattern baldness by minoxidil: a case report.
        Cutis. 1981; 28: 515-558
        • Szpunar GJ
        • Dalm EP
        • Albert KS
        The bioavailability of 2% and 3% minoxidil solutions relative to a 2.5 mg oral minoxidil tablet.
        Pharmaceutical Research. 1986; 3: 114S
        • DeVillez RL
        Topical minoxidil therapy in hereditary androgenetic alopecia.
        Arch dermatol. 1985; 121: 197-202
        • Storer JS
        • Brzuskiewicz J
        • Floyd H
        • et al.
        Review: topical minoxidil for male pattern baldness.
        Am J Med Sci. 1986; 291: 328-333
        • Kreindler TG
        Topical minoxidil in early androgenetic alopecia.
        J Am Acad dermatol. 1987; 16: 718-724
        • Katz HI
        • Hein NT
        • Prawer SE
        • et al.
        Long-term efficacy of topical minoxidil in male pattern baldness.
        J Am Acad dermatol. 1987; 16: 711-718
        • Savin RC
        Use of topical minoxidil in the treatment of male pattern baldness.
        J Am Acad dermatol. 1987; 16: 696-704
        • Rietschel RL
        • Duncan SH
        Safety and efficacy of topical minoxidil in the management of androgenetic alopecia.
        J Am Acad dermatol. 1987; 16: 677-684
        • Olsen EA
        • Weiner MS
        • DeLong ER
        • et al.
        Topical minoxidil in early male pattern baldness.
        J Am Acad dermatol. 1985; 13: 185-192
        • Roberts JL
        Androgenetic alopecia: treatment results with topical minoxidil.
        J Am Acad dermatol. 1987; 16: 705-710
        • Pestana A
        • Olsen EA
        • DeLong ER
        • et al.
        Effect of ultraviolet light on topical minoxidil-induced hair growth in advanced male pattern baldness.
        J Am Acad dermatol. 1987; 16: 737-744
        • Price VH
        Topical minoxidil (3%) in extensive alopecia areata, including long-term efficacy.
        J Am Acad dermatol. 1987; 16: 730-736
        • Price VH
        Topical minoxidil in extensive alopecia areata.
        Dermatologica. 1987; 175: 36-41
        • Baral J
        Scalp comedones after topical minoxidil.
        J Am Acad dermatol. 1985; 13: 1051
        • Staudt R
        Scalp comedones after topical application of minoxidil.
        Derm Beruf Unwelt. 1987; 35: 32
        • Javier R
        • Dumler F
        • Park H
        • et al.
        Long-term treatment with minoxidil in patients with severe renal failure.
        J Cardiovasc Pharmacol. 1980; 2: 149-152
        • Earhart RN
        • Ball J
        • Nuss DD
        • et al.
        Minoxidil-induced hypertrichosis: treatment with calcium thioglycolate depilatory.
        South Med J. 1977; 70: 442-443
        • Gilmore E
        • Weil J
        • Chidsey III, CA
        Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade.
        N Engl J Med. 1970; 282: 521-527
        • Ryan JR
        • Jain AD
        • McMaho FG
        Minoxidil treatment of severe hypertension.
        Curr Ther Res. 1975; 17: 55-56
        • Traub YM
        • et al.
        Treatment of severe hypertension with minoxidil.
        Isr J Med Sci. 1975; 11: 991-998
        • Olsen EA
        • DeLong ER
        • Weiner MS
        Long-term followup of men with male pattern baldness treated with topical minoxidil.
        J Am Acad dermatol. 1987; 16: 688-695
        • Franz TJ
        Percutaneous absorption of minoxidil in man.
        Arch dermatol. 1985; 121: 203-206